SC
CAMP icon

SummitTX Capital’s CAMP4 Therapeutics CAMP Stock Holding History

SummitTX Capital’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5M Buy
+339,521
New +$1.61M 0.05% 361

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SummitTX Capital's CAMP Position: Q1 2026 in Review

SummitTX Capital opened a new position in CAMP4 Therapeutics (CAMP) in Q1 2026: 339,521 shares worth $1.5M. The stake represents 0.05% of the portfolio and ranks #361 among its holdings.

46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

  • SummitTX Capital held 339,521 shares of CAMP4 Therapeutics worth $1.5M as of Q1 2026.
  • CAMP4 Therapeutics was a new SummitTX Capital position in Q1 2026.
  • CAMP4 Therapeutics made up 0.05% of SummitTX Capital's portfolio in Q1 2026, its #361 holding.
  • 46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.